TV-Beitrag-National Institutes of Health: Will Dendritic Cell Subsets help us address the challenges of Cancer, Autoimmunity and Viral Diseases?
/in Externe Meldungen /von IOZKHER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
/in Breast Cancer, Dendritic Cells, International Publications /von 2012-01-17 / Cancer 2012 Sep;118(17):4354-62Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2012-01-10 / JOP 2012 Jan;13(1):45-53Immunotherapy for metastatic colorectal cancer: present status and new options
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2012-01-03 / Scand. J. Gastroenterol. 2012 Mar;47(3):315-24The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-01-01 / Curr. Top. Microbiol. Immunol. 2012;351:181-220Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2012-01-01 / Methods Mol. Biol. 2012;797:177-204[Prostate carcinoma: vaccination as a new option for treatment]
/in Dendritic Cells, International Publications, Prostate Cancer /von 2012-01-01 / Urologe A 2012 Jan;51(1):44-9A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2012-01-01 / J Immunother 2012 Jan;35(1):54-65Inhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress
/in Hyperthermia, International Publications /von 2012-01-01 / Apoptosis 2012 Jan;17(1):102-12
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution